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Background: Naja naja atra venom (NNAV) displays diverse pharmacological actions including analgesia, anti-inflammation
and immune regulation.
In this study, we investigated the effects of NNAV on pulmonary fibrosis and its mechanisms of action.
Methods: To determine if Naja naja atra venom (NNAV) can produce beneficial effects on pulmonary fibrosis, two marine
models of pulmonary fibrosis were produced with bleomycin (BLM) and lipopolysaccharide (LPS). NNAV (30, 90, 270 μg/kg)
was orally administered once a day started five days before BLM and LPS until to the end of experiment. The effects of
NNAV treatment on pulmonary injury were evaluated with arterial blood gas analysis, hydroxyproline (HYP) content
assessment and HE/Masson staining. The effects of NNAV treatment on inflammatory related cytokines, fibrosis
related TGF-β/Smad signaling pathway and oxidative stress were examined.
Results: The results showed that NNAV improved the lung gas-exchange function and attenuated the fibrotic
lesions in lung. NNAV decreased IL-1β and TNF-α levels in serum in both pulmonary fibrosis models. NNAV
inhibited the activation of NF-κB in LPS-induced and TGF-β/Smad pathway in BLM-induced pulmonary fibrosis.
Additionally, NNAV also increased the levels of SOD and GSH and reduced the levels of MDA in BLM-induced
pulmonary fibrosis model.
Conclusions: The present study indicates that NNAV attenuates LPS- and BLM-induced lung fibrosis. Its mechanisms
of action are associated with inhibiting inflammatory response and oxidative stress. The study suggests that NNAV
might be a potential therapeutic drug for treatment of pulmonary fibrosis.
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Pulmonary fibrosis is a progressive and lethal lung disease
characterized by accumulation of extracellular matrix and
loss of pulmonary function [1]. The disease can be idio-
pathic or developed as a complication of many respiratory
and systemic diseases. Although the etiology of pulmonary
fibrosis has not as yet been clearly elucidated, some putative
mechanisms involved in the pathogenesis including inflam-
mation and oxidative stress have been intensively explored
[2,3]. Inflammation is the initial response following lung* Correspondence: qinzhenhong@suda.edu.cn
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unless otherwise stated.injury. Once activated, inflammatory cells such as neutro-
phils and macrophages accumulate in the lower airways and
consequently release harmful amounts of reactive oxygen
species and some pro-inflammatory cytokines and growth
factors that regulate the proliferation and secretary activity
of alveolar fibroblasts in alveolar wall. The activated fibro-
blasts produce increasing amounts of matrix proteins, which
distort the normal lung architecture and affect gas exchange.
Therefore, inhibition of inflammation and oxidative stress
represents possible therapeutic strategies [4-8]. Actually, the
present treatment recommendations for lung fibrosis are
corticosteroid combined with immunosuppressants, anti-
inflammatory and anti-oxidant drugs. Unfortunately, the
therapeutic effects of these treatments are limited, nonspe-
cific, and largely ineffective [9]. Thus the development of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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needed.
Snake venoms, as complementary and alternative medi-
cine, display diverse pharmacological effects due to their
complex compositions including toxins, enzymes and other
bioactive factors. Naja naja atra (Chinese cobra) and its
toxic venoms are considered as a medicine in Chinese folk
medicine. Our recent research showed that Naja naja atra
venom (NNAV) or some specific component of the crude
venom (cobrotoxin) significantly suppressed inflammation
and rheumatoid arthritis in animal models [10,11]. Some
investigators also reported certain fractions isolated from
NNAV have a remarkable free radical scavenging activity
in mice [12].
In the light of the association of pulmonary fibrosis
pathogenesis with inflammation and cytokines, we spec-
ulated that NNAV might have therapeutic effects in lung
fibrosis. To test this possibility, we applied two murine
pulmonary fibrosis models. One was inflammation-related
fibrosis mouse model induced by lipopolysaccharide
(LPS), and another was bleomycin (BLM)-induced rat
pulmonary fibrosis. On the basis of our previous re-
port, in this study NNAV was reversible denatured by
heat and administered orally [10].Methods
Animals
One hundred Kunming (KM) mice (half male and half
female, 18–20 g) and 60 male Sprague–Dawley rats
(180-220 g) were obtained from the Shanghai SLAC La-
boratory Animal Co. Ltd. All animals were housed in a
controlled ambient temperature (22±2°C), humidity (40%-
70%), a 12 h light/dark cycle with free access to food and
water. Animals were acclimated to the housing conditions
for 2–3 days before experiments. All experiments and sur-
gical procedures were approved by the Animal Care and
Use Committee of Soochow University, which complies
with the National Institute of Health Guide for the Care
and Use of Laboratory Animals.Reagents and drugs
Naja naja atra venom, purchased from Rainbow Snake
Farm (Yu Jiang, Jiangxi Province, China), which is certi-
fied for having standard biological activities and compo-
sitions. NNAV contains neurotoxin 8%-10%, cardiotoxin
35%–40%, nerve growth factor 1%-2%, phospholipase A2
8%, and cobra venom factor (CVF). The doses of NNAV
were decided with our previous studies [13]. It was dis-
solved in sterile saline and heated to 100°C for 10 min,
then placed at room temperature (RT) for renaturation
and stored at 4°C until use [10]. Both LPS (Sigma-Aldrich
Co., USA) and bleomycin (Nippon Kayaku Co Lt, Japan)
were dissolved in normal saline.Pulmonary fibrosis models and drug administration
Lipopolysaccharide (LPS)-induced model: One hundred
male KM mice were randomly divided into the control
group, the model group and the NNAV (30, 90, 270 μg/kg)
groups. Animals were intragastrically administrated with
normal saline or NNAV once daily for 4 days followed by
intraperitoneal injection of LPS (Sigma, USA, 5 mg/kg in
0.9% saline water) on the 5th day except the control group.
To observe the acute protective effects of NNAV, half of
mice in every group were sacrificed 6 h after LPS injection.
The rest were subjected to intraperitoneal injection of LPS
once a week for 8 weeks to induce chronic pulmonary fi-
brosis. During the chronic induction period, mice were ad-
ministered with NNAV or saline once a day until to the
end of the experiment.
Bleomycin (BLM)-induced model: Similar to the LPS
model, 60 rats were randomly divided into five groups.
To induce pulmonary fibrosis, rats were anesthetized
with intraperitoneal injection of 4% chloral hydrate (Sigma,
Shanghai, China). BLM solution (Nippon Kayaku Co Ltd,
Tokyo, Japan, 5 mg/kg in 0.9% saline water) was intratra-
cheally instilled into all the rats except those in control
group [5]. Rats in control group were intratracheally
administered the same volume of 0.9% saline. NNAV
(30, 90, 270 μg/kg) was given orally once a day for
4 days before BLM administration and then was con-
tinued for 8 weeks until to the end of the study. All
rats were killed 8 weeks after bleomycin exposure.
Assay of MDA, SOD and GSH
MDA, SOD and GSH in serum and lung tissues were
determined with kits following the manufacturer’s in-
structions (Nanjing Jiancheng Bioengineering Institute,
China).
Arterial blood gas analysis (BGA)
Arterial blood was collected from abdominal aortic artery
after 8 weeks NNAV administration. The blood samples
were sealed and immediately sent to a local hospital for
analysis (No.100 Veterans Hospital, Suzhou, China). BGA
was used to evaluate the impairment of respiratory func-
tion. The blood power of hydrogen (pH), partial pressure
of carbon dioxide (PCO2), partial pressure of oxygen
(PO2), oxygen saturation (SO2) and the levels of lactic
acid were measured by blood gas analyzer (Radiometer
medical equipment Co. Ltd, Copenhagen, Denmark).
ELISA
Serum IL-1β and TNF-α were determined with ELISA
kits according to manufacturer’s protocol (Hushang Bio
Technology Co Ltd, Shanghai, China). Samples were
measured with a Bio-Rad Benchmark microplate reader at
a wavelength of 450 nm. The concentrations of IL-1β and
TNF-α were derived from the respective standard curves.
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Pulmonary collagen contents were analyzed with a kit
(Nanjing Jiancheng Bioengineering Institute, Nanjing,
China) 8 weeks after application of LPS or BLM. The
lung tissue was hydrolyzed with NaOH at 95–100°C for
20 min. After neutralization with HCl, the hydrolyzates
were diluted with distilled water. Hydroxyproline con-
tent in the tissue was assessed with a spectrophotometer
at 550 nm in the presence of dimethylaminobenzalde-
hyde. The results were calculated as μg of hydroxypro-
line per gram of wet lung tissue [14].
Histopathological examination
Lung was fixed in 10% buffered formalin solution, em-
bedded in paraffin, sectioned at 5 μm and subjected to
hematoxylin-eosin (HE) and Masson’s trichrome staining
to detect inflammation or collagen deposition.
Western blot analysis
Lung was rinsed with saline to remove blood. The lung
was then homogenized and centrifuged at 10,000 rpm
for 5 min. Thereafter, the supernatant was collected and
protein concentrations were determined with the BCA
Protein Assay Reagent (Pierce, Rockford, IL, USA). Proteins
were resolved with sodium dodecyl sulfate polyacrylamideFigure 1 Effects of NNAV on pulmonary index and HYP content. Pulm
for 8 weeks or a single intratracheal administration of bleomycin. Mice and rats w
continued until to the end of experiment. (A) Pulmonary index 6 h after LPS trea
index 8 weeks after BLM treatment. (D) HYP levels 8 weeks after LPS treatment. (
compared to control group; #P<0.05, ##P<0.001, NNAV-treated groups compagel electrophoresis (SDS-PAGE) on a 10% gel. After elec-
trophoresis, proteins were immediately transferred to a
nitrocellulose membrane (Bio-Rad Laboratories, Hercules,
CA, USA) at 30 mA for 2 h. The membranes were blocked
with 5% nonfat dry milk in TBS/Tween (25 mM Tris–HCl,
0.14 M NaCl, 2% Tween 20) at 4°C overnight. Membranes
were incubated with primary antibody for one h and the
antibody dilutions were as follows: anti-TGF-β1, 1:1000;
anti-Smad7, 1:500; anti-p-Smad2/3, 1:500; anti-Collagen I,
1:1000. Washing between and after antibody incubation
steps was performed three times for 10 min each with TBS/
Tween buffer. Then, the membrane was incubated with
fluorescent secondary antibody and scanned with Odyssey®
Western Blot Analysis system (LI-COR, Lincoln, NE, USA).
The signal intensity of primary antibody binding was quanti-
tatively analyzed with Sigma Scan Pro 5 and was normalized
to the loading control β-actin.
Immunofluorescence analysis
Lung tissues in acute phase of LPS-induced mice was
fixed in 10% buffered formalin solution, embedded in par-
affin, sectioned at 5 μm thickness and deparaffinized and
hydrated using a xylene solution and graded ethanol. After
antigen retrieval, sections were rinsed in deionized water.
Next, the sections were incubated in 5% bovine serumonary fibrosis was induced with intraperitoneal injection of LPS once a week
ere administered saline or NNAV orally 4 days prior to LPS and BLM and
tment. (B) Pulmonary index 8 weeks after LPS treatment. (C) Pulmonary
E) HYP levels 8 weeks after LPS treatment. *P<0.05, **P<0.001, model group
red to model group. N =10 per group.
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room temperature to reduce nonspecific binding of anti-
body. Sections were then rinsed three times with 1% PBS,
covered with primary antibody against NF-κB (NF-κB,
1:100, Cell signaling technology, USA), and incubated in a
humidity chamber at 37°C for 60 min. After rinsing three
times with 1% PBS, secondary antibodies were added to the
sections and incubated in the humidity chamber at 37°C
for 30 min. Sections were rinsed, added with DAPI in a hu-
midity chamber at 37°C for 15 min. Sections were rinsed
with deionized water, dehydrated with graded ethanol and
sealed with neutral resins. Sections were examined with a
confocal laser scanning microscope.
Statistical analysis
All data were presented as mean ± SD, and SPSS16.0
software (SPSS, Inc., USA) was used for statistical ana-
lysis. Statistical significance was defined at P <0.05.
Results
Effects of NNAV on pulmonary index and hydroxyproline
(HYP) content
Compared to the control group, pulmonary index (lung
weight/ body weight ratio) significantly increased in the LPS-
and BLM-induced pulmonary fibrosis models (Figure 1A, BFigure 2 Arterial blood gas analysis in BLM-induced pulmonary fibros
and continued until to the end of experiment. Arterial blood was collected
including power of hydrogen (pH, A), lactic acid (B), partial pressure of carb
saturation (SO2, E) were measured. *P<0.05, BLM group compared to cont
N =10 per group.and C; P<0.05). NNAV treatment had no significant effect
on pulmonary index 6 h after LPS injection (Figure 1A), but
markedly decreased it 8 weeks after LPS, Figure 1B; P<0.05).
Similarly, NNAV also significantly reduced the pulmonary
index in BLM-induced model (Figure 1C; P<0.05).
Hydroxyproline (HYP) is the main component in
extracellular collagen, which is the hallmark of pul-
monary fibrosis [4]. In this study, we observed that
both LPS-induced (chronic phase) and BLM-induced
pulmonary fibrosis models had higher HYP levels than
that in the control groups (Figure 1D, E), while NNAV
treatment significantly attenuated the elevations in hy-
droxyproline levels in lung tissues (Figure 1D, E; P<0.05).
Effects of NNAV on blood gas analysis (BGA) in BLM-induced
pulmonary fibrosis
To evaluate the changes in lung function in pulmonary
fibrosis, we analyzed the arterial blood gas using acid–
base status parameters: power of hydrogen (pH), lactic
acid and gas exchange parameters: partial pressure of
carbon dioxide (PCO2), partial pressure of oxygen (PO2)
and oxygen saturation (SO2). The data showed that rats
treated with BLM had a lower value of blood pH (Figure 2A)
and a higher level of lactic acid (Figure 2B) than that in con-
trol group (p<0.05). PCO2 value in the model group wasis. Rats were administered saline or NNAV orally 4 days prior to BLM
in the syringe and sealed. Key indicators of blood gas testing
on dioxide (PCO2, C), partial pressure of oxygen (PO2, D), oxygen
rol group; #P<0.05, NNAV-treated groups compared to BLM group.
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68.43±12.28 mmHg, p<0.05), while both PO2 value
(Figure 2D) and SO2 value (Figure 2E) were significantly
decreased (from 83.33±13.13 to 60.57±11.69 mmHg for
PO2 value and from 90.53±3.13 to 74.63±16.36 percent
for SO2 value, p<0.05). NNAV treatment significantly ele-
vated the value of blood pH and reduced lactic acid con-
tent (p<0.05 vs control). Consistent with acid–base status
parameters, low dose, middle dose and high dose of
NNAV all significantly increased PO2 and SO2 values and
decreased PCO2 value (Figure 2C, D and E).Effects of NNAV on the LPS- and BLM-induced
histopathological changes in the lungs
Using the HE staining and Masson staining, we found
that lung tissue sections from the control group displayed
normal structure and no inflammatory or fibrotic lesions
(Figure 3A(a), B(a), C(a), D(a)), while a few light blue col-
lagen deposition was observed in the alveolar septa in
Masson stained section. In LPS-treated groups (acuteFigure 3 Effects of NNAV on the histopathological changes in the lun
Animals were treated as described in the legend to Figure 1. Lung tissue w
trichrome. Inflammatory cell infiltration (▲) and the blue color collagen de
LPS. (a) Control. (b) LPS. (c) LPS + NNAV 30 μg/kg. (d) LPS + NNAV 90 μg/k
LPS-treated lung. (c) LPS + NNAV 30 μg/kg. (d) LPS + NNAV 90 μg/kg. (e) L
(c) BLM + NNAV 30 μg/kg. (d) BLM + NNAV 90 μg/kg. (e) BLM + NNAV 270
BLM + NNAV 30 μg/kg.D(d) BLM + NNAV 90 μg/kg. D(e) BLM + NNAV 270phase and long-term) and BLM-treated group, the alveolar
septa were significantly thickened (Figure 3A(b), B(b),
C(b)), accompanied by infiltration of inflammatory cells.
In addition, the blue collagen deposition was markedly in-
creased in the alveolar septa (Figure 3D(b). NNAV treat-
ment (Figure 3A(d, e), B(d, e), C(d, e)) at middle and high
dose markedly reduced the infiltration of inflammatory
cells, accumulation of collagen deposition and reduced
the wall thickness of alveolar septa (Figure 3D(c, d, e)).Effects of NNAV on serum levels of IL-1β and TNF-α
To determine whether NNAV rendered the protection by
inhibiting inflammatory process, we analyzed the serum in-
flammatory cytokines IL-1β and TNF-α in LPS-induced
(acute phase) and BLM-induced pulmonary fibrosis. The
data showed that TNF-α (Figure 4A, C) and IL-1β (Figure 4B,
D) dramatically up-regulated not only in the acute phase of
LPS-induced model but also 8 weeks later in the BLM-
induced pulmonary fibrosis. There was a significant reduc-
tion in the levels of these cytokines in NNAV-treatedg tissue (HE staining and Masson’s trichrome staining, ×400).
as fixed in 10% formalin, sectioned and stained with HE and
position (↑) in the lung tissue were found. HE staining: (A) Six h after
g. (e) LPS + NNAV 270 μg/kg. (B) Eight weeks after LPS. (a) Control. (b)
PS + NNAV 270 μg/kg. (C) Eight week after BLM. (a) Control. (b) BLM.
μg/kg. (D) Masson’s trichrome staining: D(a) Control. D(b) BLM. D(c)
μg/kg.
Figure 4 Effects of NNAV on serum levels of IL-1β and TNF-α. Animals were treated as described in the legend to Figure 1. The blood was
collected from abdomen artery and serum IL-1β and TNF-α were measured with ELISA. (A) TNF-α in acute phase of LPS-treated. (B) IL-1β in acute
phase of LPS-treated. (C) TNF-α of BLM-treated. (D) IL-1β of BLM-treated *P<0.05, BLM group compared to control group; #P<0.05, NNAV treated
groups compared to BLM alone group. N =4 per group.
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results indicated that NNAV attenuated the pulmonary
fibrosis, in part, by its anti-inflammatory effects.
Effects of NNAV on the activation of NF-κB in LPS-induced
lung fibrosis
The transcription factor NF-κB plays a key role in im-
mune response and lung fibrosis. To determine the mo-
lecular mechanisms of NNAV’s anti-inflammatory effects,
we explored the effects of NNAV on the activation of NF-
κB with immunofluorescence. Data showed that p65 was
distributed mainly in the cytoplasm in control lungs, while
it rapidly translocated into the nucleus when mice were
injected with LPS (6 h), which denoted the activation of
NF-κB. NNAV (90 and 270 μg/kg) significantly reduced
the translocation of p65 from the cytoplasm to the nu-
cleus (Figure 5). These results indicated that the inhibition
of NF-κB was involved in the protection of NNAV on the
pulmonary fibrosis.
Effects of NNAV on TGF-β/Smad pathway in the lung
tissue
It is well accepted that TGF-β is a key cytokine in the
process of fibrogenesis via the intracellular signaling path-
way involving Smad2 and Smad3. In order to determinethe role of the TGF-β/Smad pathway in NNAV-mediated
anti-inflammation and anti-fibrosis effects, we detected
the protein expression of TGF-β1, p-Smad2/3, collagen I
(a marker of fibroblast activation) and Smad7 (a negative
regulative protein by preventing phosphorylation of Smad2/
3) [15-17]. We found that BLM-treated model group had a
dramatic increase in the levels of TGF-β1, p-Smad2/3 and
collagen I in lung tissue, accompanied by a significant de-
crease in the levels of Smad7 (Figure 6). NNAV treatment
caused a significant decrease in TGF-β1, phosphorylated
Smad2/3 and type I collagen levels (Figure 6 A, B and C,
p<0.05) concomitant with an elevation in Smad7 levels
(Figure 6D, p<0.05). These results indicate that NNAV
can inhibit the TGF-β/Smad signaling pathway.Effects of NNAV on oxidative stress
Oxidative stress is one of prominent mechanisms involved
in the pathogenesis of pulmonary fibrosis [18,19]. To explore
whether NNAV’s protection was related to anti-oxidative ef-
fect, we determined the levels of SOD, GSH and MDA in
lung tissue and in serum. The results showed that BLM
decreased the levels of SOD (Figure 7A, D) and GSH
(Figure 7B, E), companied with an increased level of
MDA (Figure 7C, F). NNAV treatment elevated the
levels of SOD and GSH and reduced the levels of MDA
Figure 5 Effects of NNAV on the nuclear translocation of NF-κB in the lung tissue. Nuclear translocation of NF-κB induced by LPS injection
was detected by confocal microscopy. (A) Expression of NF-κB p65 in control group. (B) Expression of NF-κB p65 in acute phase of LPS-treated
group. (C) Expression of NF-κB p65 in Low dose of NNAV-treated group (30 μg/kg). (D) Expression of NF-κB p65 in Middle dose of NNAV-treated
group (90 μg/kg). (E) Expression of NF-κB p65 in High dose of NNAV-treated group (270 μg/kg). Scale bar equals 20 μm. See text for details.
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results suggested that NNAV could attenuate the BLM-
induced oxidative stress.
Discussion
In this study, we present experimental evidence demon-
strating the protective effects of NNAV on pulmonary fi-
brosis. NNAV not only ameliorated histopathological
impairment in murine lung fibrosis models but also im-
proved the lung gas-exchange function. The first model
is LPS-induced mouse lung fibrosis which is inflamma-
tion related [20]. We assessed the effects of NNAV on
acute phase (6 h) and chronic phase (8 weeks) in LPS-
induced lung inflammatory injury. Consistent with the
report, LPS injection resulted in considerable lung tissue
injury in a few hours, which is characterized by an in-
creased level of pro-inflammatory cytokines, neutrophil
accumulation in the alveolar and interstitial space and
alveolar wall thickening. NNAV markedly attenuated
these inflammatory responses. To further validate the
protection, we observed the effects of NNAV in the
chronic phase of this model. When LPS administration
continued for 8 weeks, the lung tissue had increasedlevels of hydroxyproline (HYP) content, collagen I and
thickness of alveolar septa, suggesting pulmonary fibro-
sis was produced. NNAV dramatically decreased the
HYP content and alleviated the lung tissue fibrosis.
After a poisonous snake bite, in which the venom is de-
livered to the veins and tissues in its native form, severe
inflammation is induced. In our study, we administered
NNAV orally and some components may be destroyed by
protease. The therapeutic dose of NNAV used in the study
was considerable small compared to a dose received by
snake bite. In addition, a previous study by Zhu et al. [10]
showed that high temperature, 100°C, cause the increased
expression of low molecular weight proteins, such as car-
diotoxin and neurotoxin. All these might attribute to its
different effects of NNAV on inflammation from a
snake bite.
The second model is BLM-induced rat pulmonary fi-
brosis. BLM is used as a chemotherapeutic agent for the
treatment of human cancer. Its common adverse effect
is pulmonary fibrosis. The intratracheal administration
of BLM can cause pulmonary fibrosis and is a commonly
used animal model for pulmonary fibrosis [21,22]. The
present results showed that BLM administration caused
Figure 6 Effects of NNAV on TGF-β/Smad pathway in the lung tissue. Animals were treated as described in the legend to Figure 1. All rats
were killed 8 weeks after bleomycin exposure. The Lung was collected, homogenized and centrifuged, and then the supernatant was collected
for Western blot analysis. (A) Protein expression of TGF-β1. (B) Protein expression of p-Smad2/3. (C) Protein expression of Collagen I. (D) Protein
expression of Smad7. Bars represent the mean ± SD of a minimum of N=6 per group. *P<0.05, BLM group compared to control group, #P<0.05,
NNAV-treated groups compared to BLM group.
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ing thickness of alveolar septa, smaller alveolar space, in-
filtration of inflammatory cells and the accumulation of
collagen deposition. NNAV treatment again markedly
reduced the accumulation of collagen deposition, de-
creased hydroxyproline content and meliorated the wall
thickness of alveolar septa. BGA remains a first-step
diagnostic approach in patients with suspected lower
pulmonary function [23,24]. The current results indi-
cated that BLM-treated rats had decreased values of pH,
PO2 and SO2 and increased levels of lactic acid and
PCO2 in contrast to control group. We found that
NNAV treatment improved lung gas exchange function.
Cellular inflammation is the pathologic hallmark in
the lung parenchyma of patients with pulmonary fibrosis
[3]. Actually the majority of animal models of fibrosis in-
cluding the above described models start with inflamma-
tion [22]. TNF-α is a key cytokine in pulmonary fibrosis,
which induces expression of adhesion molecule, recruit-
ment of inflammatory cells into the lungs and synthesis
of other cytokines [3,4]. In our study, both LPS- and
BLM-induced models are characterized by the increasedlevels of TNF and IL-1β in serum. NNAV significantly
reduced the increases in TNF-α and IL-1β levels in both
models. Therefore, these results suggest that NNAV
might produce the protection on lung fibrosis by anti-
inflammatory effect. It is generally accepted that the
regulation of pro-inflammatory cytokines is mediated, at
least partly, by NF-κB. Therefore, NF-κB can be taken as
a potential target for the therapy of lung fibrosis. Since
LPS is the typical activator of NF-κB pathway, we ob-
served the effects of NNAV in the acute phase of LPS-
induced pulmonary injury model. NNAV decreased the
LPS-induced the nuclear translocation of NF-κB. This
provides one possible mechanism of for NNAV’s inhibi-
tory effect on pro-inflammatory cytokines.
Transforming growth factor β (TGF-β) is implicated in
the initiation and progression of fibrosis [3]. The profi-
brotic effects of TGF-β are mediated by its multiple ac-
tions, including induction of myofibroblasts, increase of
matrix synthesis, and inhibition of collagen breakdown.
Most of these effects are thought to be mediated
through the Smad signaling pathway. Once activated,
TGF-β signals through transmembrane receptors that
Figure 7 Effects of NNAV on the levels of MDA, SOD and GSH. Animals were treated as described in the legend to Figure 1. The blood was
collected from abdomen artery and SOD, GSH and MDA were measured in the serum and lung tissue. (A) SOD in the lung tissue. (B) GSH in the
lung tissue. (C) MDA in the lung tissue. (D) SOD in the serum. (E) GSH in the serum. (F) MDA in the serum. *P<0.05, compared to control group,
#P<0.05, NNAV-treated groups compared to BLM alone group. N =10 per group.
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ulates transcription of important target genes, including
pro-collagen I and III. The phosphorylation of Smad2/3
can be inhibited by Smad7 [15]. It has been established
that alveolar macrophages stimulated by BLM secrete
large quantities of biologically active TGF-β. Our results
demonstrated that NNAV lowered the total and biologic-
ally active TGF-β levels in the lung tissue compared with
BLM-treated model group. There was also a significantdifference in the levels of phosphorylation of Smad2/3 and
Smad7 between the BLM-treated model group and NNAV-
treated groups. The expression of collagen I was markedly
upregulated by BLM. NNAV greatly reduced the expression
of collagen I. These suggest that NNAV inhibits the TGF-
β-mediated transcription of profibrotic genes downstream
of the phosphorylation and nuclear translocation of Smads.
Oxidant stress is a key player in the pathogenesis of pul-
monary fibrosis [18,19]. Both patients and experimental
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oxidant burden and disturbed antioxidant/oxidant balance
[3]. Several studies also suggest that reactive oxygen spe-
cies can cause activation of growth-regulatory cytokines,
including TGF-β. In light of the remarkable free radical
scavenging activity of some fractions of NNAV, in this
study we demonstrated that NNAV did affect antioxidant/
oxidant balance in BLM-induced lung fibrosis. The evi-
dence is that NNAV treatment elevated the levels of SOD
and GSH but reduced level of MDA both in lung tissue
and in serum.
Some snake toxins have anticoagulant effects. Mizuno
et al. [25] described factor X-binding protein (X-bp), an
anticoagulant protein, from snake venom. And one of
the components of Naja nigricollis venom, phospholip-
ase A2 (PLA2), has also been shown to be an anticoagu-
lant [26]. In addition, treatment of pulmonary fibrosis
patients with heparin and warfarin (anticoagulants) re-
duces the coagulation that occurs in the lungs as a result
of vascular injury, and endothelial disruption [27]. Whether
NNAV ameliorated pulmonary fibrosis partly through anti-
coagulation action needs to be addressed in the future.
Conclusions
In summary, the present study demonstrated that NNAV
inhibited LPS- and BLM-induced pulmonary fibrosis and
improved gas-exchange function. This protection is asso-
ciated with anti-inflammatory and anti-oxidative capability
of NNAV. The study suggests a potential therapeutic use-
fulness of NNAV on pulmonary fibrosis.
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